Selective glycosidase inhibitors and uses thereof
View Patent ↗The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
1. A compound which is
or a pharmaceutically acceptable salt thereof.
2. A compound which is
3. A compound which is
in the form of a pharmaceutically acceptable salt thereof.
4. A compound which is
or a pharmaceutically acceptable salt thereof.
5. A compound which is
6. A compound which is
in the form of a pharmaceutically acceptable salt thereof.
7. A compound which is
or a pharmaceutically acceptable salt thereof.
8. A compound which is
9. A compound which is
in the form of a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound which is
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 wherein the compound is
12. The pharmaceutical composition of claim 10 wherein the compound is
in the form of a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound which is
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 wherein the compound is
15. The pharmaceutical composition of claim 13 wherein the compound is
in the form of a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a compound which is
or a pharamaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 wherein the compound is
18. The pharmaceutical composition of claim 16 wherein the compound is
in the form of a pharmaceutically acceptable salt thereof.
19. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
20. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
21. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
22. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 4 or a pharmaceutically acceptable salt thereof.
23. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 5 .
24. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 6 in the form of a pharmaceutically acceptable salt thereof.
25. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 7 or a pharmaceutically acceptable salt thereof.
26. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 8 .
27. A method of treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 8 in the form of pharmaceutically acceptable salt thereof.
28. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
29. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
30. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
31. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 4 or a pharmaceutically acceptable salt thereof.
32. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 5 .
33. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 6 in the form of a pharmaceutically acceptable salt thereof.
34. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 7 or a pharmaceutically acceptable salt thereof.
35. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 8 .
36. A method of treating Parkinson's disease in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 9 in the form of pharmaceutically acceptable salt thereof.
37. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
38. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
39. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
40. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 4 or a pharmaceutically acceptable salt thereof.
41. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 5 .
42. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 6 in the form of a pharmaceutically acceptable salt thereof.
43. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 7 or a pharmaceutically acceptable salt thereof.
44. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 8 .
45. A method of treating Progressive supranuclear palsy in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 9 in the form of pharmaceutically acceptable salt thereof.